R Panaccione

Summary

Affiliation: University of Calgary
Country: Canada

Publications

  1. ncbi request reprint Advances in medical therapy of inflammatory bowel disease
    Remo Panaccione
    Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada
    Curr Opin Pharmacol 5:566-72. 2005
  2. pmc Postoperative complications following colectomy for ulcerative colitis: a validation study
    Christopher Ma
    Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, Alberta, Canada
    BMC Gastroenterol 12:39. 2012
  3. doi request reprint Evolving definitions of remission in Crohn's disease
    Remo Panaccione
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology, University of Calgary, Calgary, Canada
    Inflamm Bowel Dis 19:1645-53. 2013
  4. doi request reprint Implementing changes in clinical practice to improve the management of Crohn's disease
    Remo Panaccione
    Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, Canada
    J Crohns Colitis 6:S235-42. 2012
  5. pmc The approach to dysplasia surveillance in inflammatory bowel disease
    Remo Panaccione
    Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, Canada
    Can J Gastroenterol 20:251-3. 2006
  6. pmc Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial
    Remo Panaccione
    University of Calgary, Calgary, Alberta, USA
    Can J Gastroenterol 25:419-25. 2011
  7. doi request reprint Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease
    R Panaccione
    Division of Gastroenterology, Department of Medicine, University of Calgary, Calgary, AB, Canada
    Aliment Pharmacol Ther 31:1296-309. 2010
  8. doi request reprint Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease
    R Panaccione
    Department of Medicine, University of Calgary, Calgary, AB, Canada
    Aliment Pharmacol Ther 28:674-88. 2008
  9. pmc Refractory Crohn's disease of the vulva treated with infliximab: a case report
    S Makhija
    Division of Gastroenterology, University of Calgary, Calgary, Canada
    Can J Gastroenterol 21:835-7. 2007
  10. doi request reprint Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab
    C Ma
    Inflammatory Bowel Disease Clinic, Departments of Medicine, University of Calgary, AB, Canada
    Aliment Pharmacol Ther 30:977-86. 2009

Collaborators

Detail Information

Publications46

  1. ncbi request reprint Advances in medical therapy of inflammatory bowel disease
    Remo Panaccione
    Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada
    Curr Opin Pharmacol 5:566-72. 2005
    ....
  2. pmc Postoperative complications following colectomy for ulcerative colitis: a validation study
    Christopher Ma
    Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, Alberta, Canada
    BMC Gastroenterol 12:39. 2012
    ..This study compares risk estimates for predictors of postoperative complication derived from administrative data against that of chart review and evaluates the accuracy of administrative coding for this population...
  3. doi request reprint Evolving definitions of remission in Crohn's disease
    Remo Panaccione
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology, University of Calgary, Calgary, Canada
    Inflamm Bowel Dis 19:1645-53. 2013
    ..Using clinical symptoms alone to inform treatment decisions in Crohn's disease (CD) may increase the risk of disease progression and complications. Treatment beyond symptoms may offer improved outcomes...
  4. doi request reprint Implementing changes in clinical practice to improve the management of Crohn's disease
    Remo Panaccione
    Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, Canada
    J Crohns Colitis 6:S235-42. 2012
    ..Clinical studies to further define optimized treatment strategies for Crohn's disease are underway and will provide future direction...
  5. pmc The approach to dysplasia surveillance in inflammatory bowel disease
    Remo Panaccione
    Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, Canada
    Can J Gastroenterol 20:251-3. 2006
  6. pmc Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial
    Remo Panaccione
    University of Calgary, Calgary, Alberta, USA
    Can J Gastroenterol 25:419-25. 2011
    ....
  7. doi request reprint Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease
    R Panaccione
    Division of Gastroenterology, Department of Medicine, University of Calgary, Calgary, AB, Canada
    Aliment Pharmacol Ther 31:1296-309. 2010
    ..In the randomized, double-blind, placebo-controlled CHARM trial, adalimumab was more effective than placebo in maintaining clinical remission for patients with moderate-to-severe Crohn's disease (CD) through 56 weeks...
  8. doi request reprint Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease
    R Panaccione
    Department of Medicine, University of Calgary, Calgary, AB, Canada
    Aliment Pharmacol Ther 28:674-88. 2008
    ..Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases of the intestine, which frequently require surgery for complications or failure of medical therapy...
  9. pmc Refractory Crohn's disease of the vulva treated with infliximab: a case report
    S Makhija
    Division of Gastroenterology, University of Calgary, Calgary, Canada
    Can J Gastroenterol 21:835-7. 2007
    ..A case of refractory vulvovaginal CD is presented and the literature of gynecological manifestations of CD and its treatment are reviewed...
  10. doi request reprint Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab
    C Ma
    Inflammatory Bowel Disease Clinic, Departments of Medicine, University of Calgary, AB, Canada
    Aliment Pharmacol Ther 30:977-86. 2009
    ..Therapy with adalimumab has been shown to be effective in Crohn's disease (CD) patients who have lost response or are intolerant to infliximab...
  11. ncbi request reprint Sequential therapies for Crohn's disease: optimizing conventional and biologic strategies
    Shani Desilva
    Inflammatory Bowel Disease Clinic, Gastroenterology Training Program, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    Rev Gastroenterol Disord 8:109-16. 2008
    ..Future studies are warranted and will likely lead to the expanded use of such agents in the treatment of CD...
  12. ncbi request reprint Novel concepts in inflammatory bowel disease
    G W Moran
    Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, AB, Canada
    Br Med Bull 109:55-72. 2014
    ..Clinical management in inflammatory bowel disease (IBD) is constantly changing. Although improvement in symptoms is of paramount importance, using this as the only surrogate marker of disease activity might underestimate disease burden...
  13. doi request reprint Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
    R Panaccione
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology, Department of Medicine, University of Calgary, Calgary, AB, Canada
    Aliment Pharmacol Ther 38:1236-47. 2013
    ..Stable remission rates have been demonstrated for up to 2 years in adalimumab-treated patients with moderately to severely active Crohn's disease enrolled in the CHARM and ADHERE clinical trials...
  14. pmc Review and clinical perspectives for the use of infliximab in ulcerative colitis
    R Panaccione
    University of Calgary, Calgary, Canada
    Can J Gastroenterol 22:261-72. 2008
    ..Where there is a lack of evidence-based information, the expert panel provides its combined opinion derived from the members' clinical experiences...
  15. ncbi request reprint Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients
    E Ricart
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 96:722-9. 2001
    ..A total of 23 patients were continued on infliximab as maintenance treatment. CONCLUSIONS: This study provides additional evidence that infliximab is safe and beneficial in clinical practice for refractory Crohn's disease...
  16. doi request reprint Inflammatory bowel disease patients who leave hospital against medical advice: predictors and temporal trends
    Gilaad G Kaplan
    Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, Alberta, Canada
    Inflamm Bowel Dis 15:845-51. 2009
    ..Thus, we determined the prevalence of self-discharge, assessed predictors of AMA status, and evaluated time trends...
  17. pmc Effect of ambient air pollution on the incidence of appendicitis
    Gilaad G Kaplan
    Division of Gastroenterology, Department of Medicine, University of Calgary, Teaching Research and Wellness Center, Calgary, Alta
    CMAJ 181:591-7. 2009
    ..The pathogenesis of appendicitis is unclear. We evaluated whether exposure to air pollution was associated with an increased incidence of appendicitis...
  18. ncbi request reprint Managing the risks of IBD therapy
    Cynthia H Seow
    University of Calgary, TRW Building, Room 6D18, Calgary, Canada
    Curr Gastroenterol Rep 11:509-17. 2009
    ..Overall, optimal management of the patient with IBD requires open dialogue between clinician and patient so that both are cognizant of the goals, benefits, and potential risks of therapy...
  19. doi request reprint Liver diseases associated with anti-tumor necrosis factor-alpha (TNF-α) use for inflammatory bowel disease
    Carla S Coffin
    Division of Gastroenterology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    Inflamm Bowel Dis 17:479-84. 2011
    ..Often treatment may be complicated by preexisting chronic liver disease. Clinicians should be aware of potential hepatic side effects and appropriate management options...
  20. pmc The inflammatory bowel diseases and ambient air pollution: a novel association
    Gilaad G Kaplan
    Division of Gastroenterology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    Am J Gastroenterol 105:2412-9. 2010
    ..The inflammatory bowel diseases (IBDs) emerged after industrialization. We studied whether ambient air pollution levels were associated with the incidence of IBD...
  21. ncbi request reprint Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada
    R Panaccione
    Department of Medicine, University of Calgary, Calgary, Canada
    Can J Gastroenterol 15:371-5. 2001
    ..001). Additionally, infliximab is the only drug therapy shown to be effective for the treatment of fistulizing Crohn's disease. In studies done to date, infliximab appears to be well tolerated and has a favourable side effect profile...
  22. ncbi request reprint Giant cell myocarditis, in a patient with Crohn's disease, treated with etanercept--a tumour necrosis factor-alpha antagonist
    C L Nash
    Department of Gastroenterology, University of Calgary, 3330 Hospital Drive Northwest, Calgary, Alberta T2N 4N1, Canada
    Can J Gastroenterol 15:607-11. 2001
    ..These authors conclude that the use of TNF-a antagonists may be considered in the treatment of life-threatening extraintestinal manifestations of inflammatory bowel disease...
  23. ncbi request reprint Population-based analysis of practices and costs of surveillance for colonic dysplasia in patients with primary sclerosing cholangitis and colitis
    Gilaad G Kaplan
    Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    Inflamm Bowel Dis 13:1401-7. 2007
    ..The aims of the present study were (1) to determine the incidence of dysplasia or CRC, (2) to assess surveillance practices, and (3) to assess the costs associated with surveillance of PSC patients...
  24. ncbi request reprint Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease
    G W Moran
    Division of Gastroenterology and Alberta IBD Consortium, Faculty of Medicine, University of Calgary, Calgary, AB, Canada
    Aliment Pharmacol Ther 38:1002-24. 2013
    ..Dermatological adverse events may be confused with extra-intestinal manifestations of IBD...
  25. ncbi request reprint Multimodal immunosuppressant therapy in steroid-refractory common variable immunodeficiency sprue: a case report complicating cytomegalovirus infection
    S A C Medlicott
    Department of Laboratory Medicine, Peter Lougheed Centre, University of Calgary, Canada
    Int J Surg Pathol 14:101-6. 2006
    ..To our knowledge, this is original documentation of duodenal CMV infection secondary to immunomodulatory therapy for steroid-refractory CVID-sprue...
  26. ncbi request reprint Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience
    Dawnelle R Topstad
    Department of Surgery, Foothills Hospital, University of Calgary, Calgary, Alberta, Canada
    Dis Colon Rectum 46:577-83. 2003
    ..The aim of this study was to evaluate the efficacy of infliximab combined with selective seton drainage in the healing of fistulizing anorectal Crohn's disease...
  27. ncbi request reprint Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease
    Remo Panaccione
    University of Calgary, Calgary, Canada
    Can J Gastroenterol 18:503-8. 2004
  28. ncbi request reprint Hematopoietic cell transplantation for Crohn's disease; is it time?
    Y Leung
    Department of Medicine, University of Calgary, Health Sciences Center, 3330 Hospital Drive NW, Calgary, Alberta, T2N 4N1, Canada
    World J Gastroenterol 12:6665-73. 2006
    ..A secondary aim was to review the above literature and determine if the studies shed further light on the mechanisms involved in the pathogenesis of CD...
  29. ncbi request reprint Adalimumab for the treatment of Crohn's disease
    Shane M Devlin
    University of Calgary Medical Clinics, The University of Calgary, Inflammatory Bowel Disease Clinic, 3330 Hospital Drive NW, Room 127, Calgary, Alberta, Canada
    Expert Opin Biol Ther 8:1011-9. 2008
    ..It is anticipated, given its clinical efficacy, its fully human nature, and the convenience of self administration that it will have a significant effect on the management of Crohn's disease...
  30. doi request reprint Optimizing the safety of biologic therapy for IBD
    Shanika De Silva
    Inflammatory Bowel Disease Clinic, University of Calgary, Room 6D30, Teaching, Research, and Wellness TRW Building, 3280 Hospital Drive NW, Calgary, AB T2N 4N1, Canada
    Nat Rev Gastroenterol Hepatol 7:93-101. 2010
    ..During treatment, patients should be closely monitored and any symptoms that develop should be dealt with early. Education of physicians and patients is also important to allow the early detection of any adverse events...
  31. doi request reprint Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up
    Shane M Devlin
    Division of Gastroenterology, Inflammatory Bowel Disease Clinic, Department of Medicine, University of Calgary, 3280 Hospital Dr NW, Calgary, Alberta, Canada T2N 4N1
    Gastroenterol Clin North Am 38:577-94. 2009
    ....
  32. doi request reprint Microscopic colitis-defining incidence rates and risk factors: a population-based study
    Jennifer J Williams
    Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    Clin Gastroenterol Hepatol 6:35-40. 2008
    ..The burden and determinants of microscopic colitis (MC) in North America are inadequately defined. We determined the incidence rate of and risk factors for MC in a well-defined North American population...
  33. doi request reprint Evidence of endothelial dysfunction in patients with inflammatory bowel disease
    Idan Roifman
    Division of Gastroenterology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    Clin Gastroenterol Hepatol 7:175-82. 2009
    ..The purpose of our study was to assess endothelial function in patients with IBD...
  34. ncbi request reprint Anti-adhesion molecule strategies for Crohn disease
    Yvette Leung
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    BioDrugs 22:259-64. 2008
    ..It is expected that these agents will offer an alternative to the anti-TNF agent class in patients with moderate to severe Crohn disease...
  35. doi request reprint Biologic therapy in Crohn's disease: state of the art
    Jennifer Jones
    Division of Gastroenterology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    Curr Opin Gastroenterol 24:475-81. 2008
    ..This review is intended to appraise the evolution and latest developments in treatment strategies and management of patients with Crohn's disease...
  36. ncbi request reprint Isolated visceral small artery fibromuscular hyperplasia-induced ischemic colitis mimicking inflammatory bowel disease
    Sen Ian Gan
    Division of Gastroenterology, Peter Lougheed Centre, University of Calgary, 3500 25th Avenue NE, Calgary, Alberta, Canada 6J4 T1Y
    Am J Gastroenterol 99:2058-62. 2004
    ..The literature is reviewed and the possible implications are discussed...
  37. ncbi request reprint Exposing the weaknesses: a systematic review of azathioprine efficacy in ulcerative colitis
    Yvette Leung
    Division of Gastroenterology and Hepatology, University of Calgary Health Sciences Centre, G 087, 3330 Hospital Drive, NW, Calgary, AB, Canada
    Dig Dis Sci 53:1455-61. 2008
    ..We performed a systematic review and meta-analysis to evaluate the clinical efficacy of 6-thioguanine anti-metabolites for the maintenance of clinical remission after standard induction with corticosteroids...
  38. ncbi request reprint The race to block TNF-alpha: the caution flag is raised again
    Gil Kaplan
    Inflammatory Bowel Disease Center, University of Calgary, Alberta, Canada
    Inflamm Bowel Dis 10:61-2. 2004
  39. ncbi request reprint Methotrexate" "lessons from rheumatology"
    Remo Panaccione
    Can J Gastroenterol 19:541-2. 2005
  40. ncbi request reprint Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial
    Jean Frederic Colombel
    Department of Hepatogastroenterology, Hopital Claude Huriez, Centre Hospitalier Universitaire de Lille, Rue Michel Polonovski, 59037 Lille, France
    Gastroenterology 132:52-65. 2007
    ....
  41. ncbi request reprint Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Intern Med 146:829-38. 2007
    ..No anti-TNF agent has been evaluated prospectively in patients with Crohn disease who had responded to another anti-TNF agent and then lost that response or were intolerant of the agent...
  42. ncbi request reprint Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
    Stephen B Hanauer
    Division of Gastroenterology, University of Chicago Medical Center, Illinois 60637, USA
    Gastroenterology 130:323-33; quiz 591. 2006
    ..A randomized, double-blind, placebo-controlled, dose-ranging trial was performed to evaluate the efficacy of adalimumab induction therapy in patients with CD...
  43. ncbi request reprint The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota
    David A Schwartz
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 122:875-80. 2002
    ..Little is known about the cumulative incidence and natural history of fistulas in Crohn's disease in the community...
  44. ncbi request reprint Natalizumab induction and maintenance therapy for Crohn's disease
    William J Sandborn
    Mayo Clinic, Rochester, Minn 55905, USA
    N Engl J Med 353:1912-25. 2005
    ..Natalizumab, a humanized monoclonal antibody against alpha4 integrin, inhibits leukocyte adhesion and migration into inflamed tissue...
  45. ncbi request reprint Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial
    Stephan R Targan
    Inflammatory Bowel Disease Center and Division of Gastroenterology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Gastroenterology 132:1672-83. 2007
    ..A randomized placebo-controlled trial evaluated the efficacy of natalizumab induction therapy in patients with Crohn's disease...
  46. ncbi request reprint Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study
    Elena Ricart
    Inflammatory Bowel Disease Clinic, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 10:207-14. 2004
    ..We sought to determine the association between EIMs and AD in patients with first-degree familial IBD and sporadic IBD...